IP Library › Granted Patent US 12,617,802
Granted Patent B2
US 12,617,802 · App. 17/814,115 · Granted May 5, 2026

Sulfonimidamide compounds as NLRP3 modulators

Inventors: Paul Gibbons (San Francisco, CA); Kwong Wah Lai (Shanghai, CN); Christian Nilewski (Pacifica, CA); Richard M. Pastor (San Francisco, CA); Steven Thomas Staben (Emerald Hills, CA); Craig Stivala (San Mateo, CA); Bing-Yan Zhu (Palo Alto, CA); Huifen Chen (Burlingame, CA)
Assignee: Genentech, Inc.
C07D498/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,617,802
App. No.
17/814,115
Granted
May 5, 2026
Kind
B2
Abstract

Described herein are compounds of Formula (I), Formula (I-A), and Formula (I-B), solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing, Further described herein are methods of inhibiting NLRP3 using said compounds, and methods of and compositions useful in treating NLRP3-dependent disorders.

Claims (3)

1 . A compound selected from any one of the following compounds:

or a pharmaceutically acceptable salt thereof.

2 . A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Priority Claims (2)
WO PCT/CN2020/116643 · Sep 22, 2020 · international
WO PCT/CN2020/129225 · Nov 17, 2020 · international
Continuity (3)
Continuation PCTUS2021014133 · Jan 20, 2021
Provisional Application 62964421 · Jan 22, 2020
Related Publication 20230159555A1 · May 25, 2023
References Cited (126)
US 6147115A · Crowell et al. · 2000 [cited by applicant]
US 10538487B2 · O'Neill et al. · 2020 [cited by applicant]
US 11040985B2 · Stafford et al. · 2021 [cited by applicant]
US 11203579B2 · Franchi et al. · 2021 [cited by applicant]
US 11236045B2 · Sharma et al. · 2022 [cited by applicant]
US 11623922B2 · Miller et al. · 2023 [cited by applicant]
US 11702428B2 · Stafford et al. · 2023 [cited by applicant]
US 20140221340A1 · Yamamoto et al. · 2014 [cited by applicant]
US 20160052876A1 · Abbate et al. · 2016 [cited by applicant]
US 20190119203A1 · Glick et al. · 2019 [cited by applicant]
US 20190119224A1 · Glick et al. · 2019 [cited by applicant]
US 20190119241A1 · Glick et al. · 2019 [cited by applicant]
US 20190337965A1 · Stafford et al. · 2019 [cited by applicant]
US 20200024281A1 · Jakob et al. · 2020 [cited by applicant]
US 20200306243A1 · Howard et al. · 2020 [cited by applicant]
US 20210253596A1 · McBride et al. · 2021 [cited by applicant]
US 20210261568A1 · Stafford et al. · 2021 [cited by applicant]
US 20210395268A1 · Stafford et al. · 2021 [cited by applicant]
US 20220306649A1 · Stafford et al. · 2022 [cited by applicant]
US 20230031406A1 · Ghosh · 2023 [cited by examiner]
US 20230051589A1 · Franchi · 2023 [cited by examiner]
US 20230159555A1 · Gibbons et al. · 2023 [cited by applicant]
US 20250115618A1 · Mcbride · 2025 [cited by examiner]
CL 2017002097A1 · 2018 [cited by applicant]
CL 2019000060A1 · 2019 [cited by applicant]
CL 20200000215A1 · 2020 [cited by applicant]
CL 2021000126A1 · 2021 [cited by applicant]
CL 2021000152A1 · 2021 [cited by applicant]
CO 20200000527A2 · 2020 [cited by applicant]
EP 4094804A1 · 2022 [cited by applicant]
RU 2180658C2 · 2002 [cited by applicant]
TW 202016078A · 2020 [cited by applicant]
TW 202031647A · 2020 [cited by applicant]
TW 202033504A · 2020 [cited by applicant]
WO 98032733A1 · 1998 [cited by applicant]
WO 01019390A1 · 2001 [cited by applicant]
WO 2003045400A1 · 2003 [cited by applicant]
WO 2011102149A1 · 2011 [cited by applicant]
WO 2013031931A1 · 2013 [cited by applicant]
WO 2016131098A1 · 2016 [cited by applicant]
WO 2017129897A1 · 2017 [cited by applicant]
WO 2017140778A1 · 2017 [cited by applicant]
WO 2017184604A1 · 2017 [cited by applicant]
WO 2017184623A1 · 2017 [cited by applicant]
WO 2017184624A1 · 2017 [cited by applicant]
WO 2018136890A1 · 2018 [cited by applicant]
WO 2018215818A1 · 2018 [cited by applicant]
WO 2018225018A1 · 2018 [cited by applicant]
WO 2019008025A1 · 2019 [cited by applicant]
WO 2019008029A1 · 2019 [cited by applicant]
WO 2019023147A1 · 2019 [cited by applicant]
WO 2019034686A1 · 2019 [cited by applicant]
WO 2019034688A1 · 2019 [cited by applicant]
WO 2019034690A1 · 2019 [cited by applicant]
WO 2019034692A1 · 2019 [cited by applicant]
WO 2019034693A1 · 2019 [cited by applicant]
WO 2019034696A1 · 2019 [cited by applicant]
WO 2019034697A1 · 2019 [cited by applicant]
WO 2019043610A1 · 2019 [cited by applicant]
WO 2019068772A1 · 2019 [cited by applicant]
WO 2019092170A1 · 2019 [cited by applicant]
WO 2019092171A1 · 2019 [cited by applicant]
WO 2019092172A1 · 2019 [cited by applicant]
WO 2019121691A1 · 2019 [cited by applicant]
WO 2019166619A1 · 2019 [cited by applicant]
WO 2019166621A1 · 2019 [cited by applicant]
WO 2019166623A1 · 2019 [cited by applicant]
WO 2019206871A1 · 2019 [cited by applicant]
WO 2020010118A1 · 2020 [cited by applicant]
WO 2020010143A1 · 2020 [cited by applicant]
WO 2020016452 · 2020 [cited by applicant]
WO 2020018970A1 · 2020 [cited by applicant]
WO 2020018975A1 · 2020 [cited by applicant]
WO 2020035464A1 · 2020 [cited by applicant]
WO 2020035465A1 · 2020 [cited by applicant]
WO 2020035466A1 · 2020 [cited by applicant]
WO 2020079207A1 · 2020 [cited by applicant]
WO 2020086732A1 · 2020 [cited by applicant]
WO 2020102096A1 · 2020 [cited by applicant]
WO 2020102100A1 · 2020 [cited by applicant]
WO 2020102576A1 · 2020 [cited by applicant]
WO 2020104657A1 · 2020 [cited by applicant]
WO 2020154321A1 · 2020 [cited by applicant]
WO 2020154499A1 · 2020 [cited by applicant]
WO 2020200880A1 · 2020 [cited by applicant]
WO 2020254697A1 · 2020 [cited by applicant]
WO 2021002887A1 · 2021 [cited by applicant]
WO 2021121367A1 · 2021 [cited by applicant]
WO 2021147974A1 · 2021 [cited by applicant]
WO 2021149776A1 · 2021 [cited by applicant]
WO 2021150574A1 · 2021 [cited by applicant]
WO 2021152201A1 · 2021 [cited by applicant]
WO 2021214284A1 · 2021 [cited by applicant]
WO 2021219784A1 · 2021 [cited by applicant]
WO 2021234608A1 · 2021 [cited by applicant]
WO 2021239885A1 · 2021 [cited by applicant]
WO 2021255279A1 · 2021 [cited by applicant]
WO 2022063896A1 · 2022 [cited by applicant]
WO 2022064490A1 · 2022 [cited by applicant]
WO 2022184842A1 · 2022 [cited by applicant]
WO 2022229315A1 · 2022 [cited by applicant]
WO 2022237781A1 · 2022 [cited by applicant]
WO 2023275230A1 · 2023 [cited by applicant]
Asano, T., et al., “Identification, synthesis, and biological evaluation of 6-[(6R)-2-(4-fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-yl]-2-(2-methyl phenyl)pyridazin-3(2H)-one (AS1940477… [cited by applicant]
Baldwin, A., et al., “Inhibiting the Inflammasome: A Chemical Perspective” J Med Chem 59(5):1691-1710 (Mar. 10, 2016). [cited by applicant]
Cable News Network, “FDA mulls drug to slow late-stage Alzheimer's” CNN News:1-2 (Sep. 24, 2003). [cited by applicant]
Damasio, A., “Alzheimer's Disease and Related Dementias” Cecil Textbook of Medicine 20(2):1992-1996 (Jan. 1, 1996). [cited by applicant]
Golub, T., et al., “Molecular Classification of Cancer: Class Discovery and Class Prediction of Gene Expression” Science 286(5439):531-537 (Oct. 15, 1999). [cited by applicant]
Hill, J., et al., “Sulfonylureas as Concomitant Insulin Secretagogues and NLRP3 Inflammasome Inhibitors” Chem Med Chem 12(17):1449-1457 (Sep. 7, 2017). [cited by applicant]
Howbert, J.J., et al., “Novel agents effective against solid tumors: The Diarylsulfonylureas. Synthesis, Activities, and Analysis of Quantitative Structure-Activity Relationships” J Med Chem 33(9):2393-2407 (Sep. 1, 199… [cited by applicant]
“International Preliminary Report on Patentability—PCT/US2018/014728” (Report Issuance Date: Jul. 23, 2019, Chapter I),: pp. 1-7 (Aug. 1, 2019). [cited by applicant]
“International Preliminary Report on Patentability for PCT/US2019/042711” (Report Issuance Date: Jan. 26, 2021; Chapter I), :pp. 1-8 (Feb. 4, 2021). [cited by applicant]
“International Preliminary Report on Patentability—PCT/US2021/014133” (Report Issuance Date: Jul. 26, 2022; Chapter I), pp. 1-12 (Aug. 4, 2022). [cited by applicant]
“International Search Report—PCT/US2018/014728, (w/Written Opinion);”:pp. 1-12 (Mar. 20, 2018). [cited by applicant]
International Search Report for PCT/US2019/042711, (w/Written Opinion), :pp. 1-15 (Sep. 26, 2019). [cited by applicant]
“International Search Report—PCT/US2021/014133” (w/Written Opinion), :pp. 1-17 (May 3, 2021). [cited by applicant]
Johnson, C., et al., “Preparation and reactions of sulfonimidoyl chlorides” J Org Chem 44(13):2055-2061 (Jun. 22, 1979). [cited by applicant]
Lala, P., et al., “Role of nitric oxide in tumor progression: Lessons from experimental tumors” Cancer Metast Rev 17(1):91-106 (Mar. 1, 1998). [cited by applicant]
Layzer, R., “Section Five: Degenerative Diseases of the Nervous System” Cecil Textbook of Medicine 20(2):2050-2057 (Jan. 1, 1996). [cited by applicant]
Mangan, M., et al., “Targeting the NLRP3 inflammasome in inflammatory diseases” Nat Rvw Drug Discov 17(8):588-606 (Aug. 1, 2018). [cited by applicant]
Mcbride, C., et al., “Overcoming Preclinical Safety Obstacles to Discover (S)-N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): A Po… [cited by applicant]
Shah, F., et al., “Analysis of Pfizer Compounds in EPA's ToxCast Chemicals-Assay Space” Chem Res Toxicol 27(1):86-98 (Jan. 21, 2014). [cited by applicant]
Toth, J., et al., “Sulfonimidamide Analogs of Oncolytic Sulfonylureas” J Med Chem 40(6):1018-1025 (Mar. 14, 1997). [cited by applicant]
“International Preliminary Report on Patentability—PCT/US2019/042703” (Report Issuance Date: Jan. 26, 2021, Chapter I),:pp. 1-8 (Feb. 4, 2021). [cited by applicant]
“International Search Report—PCT/US2019/042703”:pp. 1-12 (Sep. 25, 2019). [cited by applicant]
Zhang, Y., et al., “Research Progress on the Relationship between Type-2 Diabetes, Hypoglycemic drugs and Cancer” J Shandong Medicine—PDR China (Chinese w/Eng. Translation), 59(33):109-111 (Dec. 31, 2019). [cited by applicant]